{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106"}]}],"title":"Adverse Events (AEs)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"88"}]}],"title":"Drug-related AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"AEs leading to discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"101"}]}],"title":"Serious Adverse Events (SAEs)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"Deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"}],"units":"Participants"}],"description":"Number of participants experiencing different types of all causality all grade adverse events","groups":[{"description":"Children and adolescents newly diagnosed with Philadelphia chromosome positive acute lymphocytic leukemia (Ph+ ALL) treated with standard multiagent chemotherapy and Dasatinib (either in tablets or Powder For Oral Suspension (PFOS)) at a dose of 60 mg/m2 daily.","id":"OG000","title":"Dasatinib Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose to 100 days following last dose (up to approximately 23 months)","title":"Number of Participants Experiencing Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}